The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. reported that Chief Medical Officer Joana Goncalves exercised employee equity awards and sold shares on September 15, 2026. She exercised options for 3,500 shares at $6.84 per share and employee warrants for 3,500 shares at $7.80 per share, acquiring 7,000 shares of common stock. She then sold an aggregate of 7,947 common shares in a series of transactions at weighted average prices generally in the low- to mid-$90s, including sales made under a Rule 10b5-1 trading plan entered into on September 19, 2025 and a separate automatic sell-to-cover transaction to satisfy tax withholding on vested restricted stock units. Following the derivative exercises, she continued to hold 193,563 option shares and 164,992 warrant shares directly.
Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal exercised employee stock options and sold common shares. On September 11, 2026, he exercised options for 8,000 shares at $12.50 and 1,459 shares at $34.39, then sold an aggregate 9,459 shares in multiple transactions between about $91.11 and $94.02 per share pursuant to a Rule 10b5-1 trading plan adopted February 11, 2026. On September 15, 2026, he sold 560 shares at $95.71 under an automatic sell-to-cover procedure for RSU tax withholding.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Executive Officer and director Lawrence Otto Klein had 2,452 shares of common stock sold on September 15, 2026 at $95.71 per share. The company states these sales were automatic, non-discretionary sell-to-cover transactions for tax withholding on vested restricted stock units, leaving Klein with 923,128 shares held directly.
Oruka Therapeutics, Inc. (ORKA) reported that General Counsel Paul T. Quinlan sold 1,039 shares of common stock on September 15, 2026 at $95.71 per share. According to the company, this automatic, non-discretionary sale was a sell-to-cover transaction to satisfy tax withholding obligations from vesting restricted stock units, leaving him with 29,995 directly held shares.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Operating Officer Laura Lee Sandler sold 906 shares of common stock on September 15, 2026 at $95.71 per share. According to a footnote, this was an automatic, non-discretionary sell-to-cover transaction to satisfy tax withholding from vesting restricted stock units, leaving her with 235,478 shares held directly.
Oruka Therapeutics, Inc. (ORKA) reported insider transactions by Chief Operating Officer Laura Lee Sandler on September 1, 2026. Sandler exercised 5,000 Employee Warrants at an exercise price of $7.80 per share into common stock, then sold 5,000 common shares in two open‑market transactions at weighted average prices around $91–$92 per share. Following the warrant exercise, Sandler held 74,996 Employee Warrants directly. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
Oruka Therapeutics, Inc. (ORKA) reported that Chief Executive Officer and director Lawrence Otto Klein exercised an employee warrant to acquire 75,000 shares of common stock at an exercise price of $7.80 per share and on the same date sold 75,000 shares of common stock in multiple open-market transactions. The sales, totaling 6,604, 63,596 and 4,800 shares, were executed at weighted average prices of $90.79, $91.90 and $92.44 per share, respectively, under a Rule 10b5-1 trading plan entered into on May 14, 2026. Following the exercise, Klein continued to hold 1,553,513 employee warrant shares, which expire on July 14, 2034.
Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler. The notice covers the planned resale of 5,000 shares of common stock on or after 09/01/2026 on NASDAQ, to be delivered through exercise of stock options for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker.
The filing also lists prior sales of Oruka common stock for Sandler during the past three months, including 5,000 shares sold on 07/01/2026 and 600 shares sold on 06/15/2026.
Oruka Therapeutics, Inc. (ORKA) received a notice that Lawrence Klein intends to sell Oruka common stock under Rule 144. The planned transaction involves up to 75,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 09/01/2026, with the shares to be acquired via exercise of stock options for cash. The notice also reports that Klein sold 1,729 shares of Oruka common stock on 06/15/2026 during the prior three months.
Oruka Therapeutics, Inc. (ORKA) has established an “at the market offering” program to sell up to $500,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent or principal under a Form S-3 shelf registration. Sales may be made from time to time on Nasdaq or other markets at prevailing market prices or in negotiated/block trades.
TD Cowen will receive up to 3.0% of the gross sales price as commission and will be deemed an underwriter. Assuming all shares are sold at $104.86 per share, Oruka would issue about 4,768,262 shares, increasing shares outstanding from 61,069,887 to up to 65,838,149. The company plans to use net proceeds for general corporate purposes, including research and development and working capital, and does not expect to pay cash dividends in the foreseeable future.
As of June 30, 2026, historical net tangible book value was $18.25 per share$24.29, implying illustrative dilution of $80.57 per share to new investors purchasing at $104.86. The filing highlights risks including broad discretion over use of proceeds, potential future dilution from additional equity and convertible securities, and share price pressure from significant or perceived future sales.